Bavarian Nordic (DB:BV3) - Aandelenkoers, Nieuws & Analyse

BV3 Overzicht aandelen

Bavarian Nordic A/S ontwikkelt, produceert en verkoopt levensreddende vaccins. Meer informatie

BV3 fundamentele analyse
Sneeuwvlok Score
Waardering	5/6
Toekomstige groei	0/6
Prestaties in het verleden	5/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Verhandeld tegen 86.1% onder onze schatting van de reële waarde

De winst groeide het afgelopen jaar met 54.6%

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Risicoanalyse

De winst zal naar verwachting de komende drie jaar met gemiddeld 0.06% per jaar dalen.

Volatiele aandelenkoers in de afgelopen 3 maanden

Aanzienlijke insider-verkoop in de afgelopen 3 maanden

Bavarian Nordic A/S Concurrenten

Biotest

XTRA:BIO3

€1.4b

Formycon

XTRA:FYB

€818.4m

2invest

XTRA:2INV

€60.4m

Dermapharm Holding

XTRA:DMP

€1.9b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Bavarian Nordic
Historische aandelenkoersen
Huidige aandelenkoers	DKK 22.62
52 Week Hoogtepunt	DKK 42.70
52 Week Laag	DKK 19.26
Bèta	1.58
11 maand verandering	-22.64%
3 maanden verandering	-34.05%
1 Jaar Verandering	10.61%
33 jaar verandering	-43.84%
5 jaar verandering	3.52%
Verandering sinds IPO	7.72%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	BV3	DE Biotechs	DE Markt
7D	-19.9%	-1.0%	-0.5%
1Y	10.6%	-16.7%	8.3%

Rendement versus industrie: BV3 overtrof de German Biotechs industrie, die het afgelopen jaar een rendement -16.7 % opleverde.

Rendement versus markt: BV3 overtrof de German markt, die het afgelopen jaar een rendement opleverde van 8.3 %.

Prijsvolatiliteit

Is BV3's price volatile compared to industry and market?
BV3 volatility
BV3 Average Weekly Movement	7.8%
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.0%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van BV3 is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 8% ) van BV3 is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen German.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1992	1,609	Paul Chaplin	www.bavarian-nordic.com

Bavarian Nordic A/S ontwikkelt, produceert en verkoopt levensreddende vaccins. Het bedrijf biedt niet-replicerende pokken- en apenpokkenvaccins onder de namen IMVAMUNE, IMVANEX en JYNNEOS; rabiësvaccin voor menselijk gebruik onder de naam Rabipur/RabAvert; tekenencefalitisvaccin onder de naam Encepur; en ebolavaccin onder de naam MVABEA. Het ontwikkelt ook MVA-BN voor de behandeling van pokken; MVA-BN RSV, dat zich in Fase III van de klinische testen bevindt voor de behandeling van respiratoir syncytieel virus; ABNCoV2 dat Fase III van de klinische testen voor de behandeling van SARS-CoV-2 heeft afgerond.

Bavarian Nordic A/S Samenvatting

Hoe verhouden de winst en inkomsten van Bavarian Nordic zich tot de beurswaarde?
BV3 fundamentele statistieken
Marktkapitalisatie	€1.78b
Inkomsten(TTM)	€149.95m
Inkomsten(TTM)	€813.68m

11.9x

Koers/Winstverhouding

2.2x

P/S-verhouding

Is BV3 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
BV3 resultatenrekening (TTM)
Inkomsten	DKK 6.07b
Kosten van inkomsten	DKK 2.33b
Brutowinst	DKK 3.74b
Overige uitgaven	DKK 2.62b
Inkomsten	DKK 1.12b

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

Mar 05, 2025

Winst per aandeel (EPS)	14.24
Brutomarge	61.57%
Nettowinstmarge	18.43%
Schuld/Eigen Vermogen Verhouding	0.1%

Hoe presteerde BV3 op de lange termijn?

Bekijk historische prestaties en vergelijking

BV3 Overzicht aandelen

Beloningen

Risicoanalyse

Bavarian Nordic A/S Concurrenten

XTRA:BIO3

€1.4b

XTRA:FYB

€818.4m

XTRA:2INV

€60.4m

XTRA:DMP

€1.9b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

New major risk - Revenue and earnings growth

Third quarter 2024 earnings released: EPS: kr.0.90 (vs kr.4.40 loss in 3Q 2023)

Investor sentiment deteriorates as stock falls 17%

First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic's Mpox Vaccine

Bavarian Nordic A/S Upgrades Earnings Guidance for the Year 2024

Bavarian Nordic A/S Receives EMA Approval of Mpox Vaccine for Adolescents

Recent updates

New major risk - Revenue and earnings growth

Third quarter 2024 earnings released: EPS: kr.0.90 (vs kr.4.40 loss in 3Q 2023)

Investor sentiment deteriorates as stock falls 17%

First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic's Mpox Vaccine

Bavarian Nordic A/S Upgrades Earnings Guidance for the Year 2024

Bavarian Nordic A/S Receives EMA Approval of Mpox Vaccine for Adolescents

Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine

CEO & President recently sold €3.2m worth of stock

Investor sentiment deteriorates as stock falls 16%

Bavarian Nordic A/S Announces First Doses of its Mpox Vaccine, Mva-BN

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Singapore

Bavarian Nordic A/S, Annual General Meeting, Apr 09, 2025

Second quarter 2024 earnings released

Bavarian Nordic A/S to Report Fiscal Year 2024 Results on Mar 05, 2025

Bavarian Nordic A/S Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to Adolescents

Investor sentiment improves as stock rises 34%

New major risk - Share price stability

Bavarian Nordic A/S Receives Positive Chmp Opinion for Including Mpox Real-World Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine

Bavarian Nordic A/S Receives EMA Filing Acceptance and Validation of the MAA for Its Chikungunya Vaccine

Investor sentiment improves as stock rises 23%

Bavarian Nordic A/S Submits Marketing Authorization Application for Its Chikungunya Vaccine Candidate to Ema

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

First quarter 2024 earnings released: kr.1.50 loss per share (vs kr.5.10 profit in 1Q 2023)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: kr.19.20 (vs kr.4.93 loss in FY 2022)

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: kr.4.40 loss per share (vs kr.0.20 profit in 3Q 2022)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Investor sentiment improves as stock rises 17%

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Investor sentiment improves as stock rises 15%

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 24%

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: kr.4.90 loss per share (vs kr.7.37 loss in FY 2021)

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

Now 22% undervalued

Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults

Chairman recently sold €68k worth of stock

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: kr.0.20 (vs kr.1.30 loss in 3Q 2021)

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic A/S Announces Covid-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial

Bavarian Nordic A/S Appoints Luc Debruyne as Board of Directors

Bavarian Nordic A/S Revises Earnings Guidance for the Full Year 2022